Skip to content

Total debt at other companies

ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
$419K+204%
Immunome logo
ImmunomeIMNM
$3.69M-22.6%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$113M+88.3%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$350.49M+4.2%
Eli Lilly logo
Eli LillyLLY
Amgen logo
AmgenAMGN

Other financials

Income statement

See full
Operating income-$60.2M-44.2%
Net income-$56.2M-52.6%
EPS (diluted)-$0.93-36.8%

Balance sheet

See full
Cash & equivalents$323.5M-30.0%
Total equity$514.0M+12.0%
Total assets$553.6M+15.8%

Cash flow

See full
Operating cash flow-$37.5M-33.5%
CapEx$60.0K
Free cash flow-$37.6M-33.7%

Valuation

See full
Market cap$1.64B+81.4%
Enterprise value$1.32B+288%

Returns & leverage

See full
Return on equity-32.3%
Debt / equity0.0×
Current ratio13.9×-10.8×

Where this comes from

Computed from long term debt + current portion long term debt + short term borrowings + operating lease liabilities + finance lease liabilities + financing obligations: $1.44M.

The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bicara Therapeutics's total debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bicara Therapeutics's total debt?
Bicara Therapeutics (BCAX) reported total debt of $1.44M in Q1 2026.
How has Bicara Therapeutics's total debt changed year-over-year?
Bicara Therapeutics's total debt increased by 143.8% year-over-year, from $591K to $1.44M.
What is the long-term trend for Bicara Therapeutics's total debt?
Over 2 years (2023 to 2025), Bicara Therapeutics's total debt has grown at a 61.3% compound annual growth rate (CAGR), from $657K to $1.71M.
What does total debt mean?
Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.